COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants.

IF 4.3 4区 医学 Q2 IMMUNOLOGY Immune Network Pub Date : 2023-03-23 eCollection Date: 2023-04-01 DOI:10.4110/in.2023.23.e13
Bill Thaddeus Padasas, Erica Españo, Sang-Hyun Kim, Youngcheon Song, Chong-Kil Lee, Jeong-Ki Kim
{"title":"COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants.","authors":"Bill Thaddeus Padasas,&nbsp;Erica Españo,&nbsp;Sang-Hyun Kim,&nbsp;Youngcheon Song,&nbsp;Chong-Kil Lee,&nbsp;Jeong-Ki Kim","doi":"10.4110/in.2023.23.e13","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination.</p>","PeriodicalId":13307,"journal":{"name":"Immune Network","volume":"23 2","pages":"e13"},"PeriodicalIF":4.3000,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/4f/in-23-e13.PMC10166656.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immune Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4110/in.2023.23.e13","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎治疗:有效治疗SARS-CoV-2变异株感染的最新进展。
2019冠状病毒病(新冠肺炎)大流行是一个多世纪以来最严重的全球卫生危机之一。自2019年发现严重急性呼吸综合征冠状病毒2型以来,它继续变异成不同的变种和亚系,使以前有效的治疗方法和疫苗无效。随着临床和药物研究的重大进展,不同的治疗策略不断被开发。目前可用的治疗方法可以根据其潜在靶点和分子机制进行广泛分类。抗病毒药物的作用是破坏严重急性呼吸系统综合征冠状病毒2型感染的不同阶段,而基于免疫的治疗主要作用于导致疾病严重程度的人类炎症反应。在这篇综述中,我们讨论了目前新冠肺炎的一些治疗方法、它们的作用模式以及它们对变异毒株的疗效。这项审查强调,需要不断评估新冠肺炎治疗策略,以保护高危人群并填补疫苗接种留下的空白。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immune Network
Immune Network Immunology and Microbiology-Immunology
CiteScore
2.90
自引率
3.30%
发文量
36
期刊介绍: Immune Network publishes novel findings in basic and clinical immunology and aims to provide a medium through which researchers in various fields of immunology can share and connect. The journal focuses on advances and insights into the regulation of the immune system and the immunological mechanisms of various diseases. Research that provides integrated insights into translational immunology is given preference for publication. All submissions are evaluated based on originality, quality, clarity, and brevity
期刊最新文献
The Role of Inflammasome-Associated Innate Immune Receptors in Cancer. STING-STAT6 Signaling Pathway Promotes IL-4+ and IFN-α+ Fibrotic T Cell Activation and Exacerbates Scleroderma in SKG Mice. Increased Inflammatory Responses in Patients With Active Disseminated Non-Tuberculous Mycobacterial Infection and High Anti-Interferon-Gamma Autoantibodies. Efficient In Vitro Plasma Cell Differentiation by B Cell Receptor Activation and Cytokine Stimulation. Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1